Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure
2002 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure
Kronenberg, F.; Kuen, E.; Ritz, E.; Konig, P.; Kraatz, G.; Lhotta, K. & Mann, J. et al. (2002)
Journal of the American Society of Nephrology, 13(2) pp. 461-469.
Documents & Media
Details
- Authors
- Kronenberg, Florian; Kuen, E.; Ritz, Eberhard; Konig, P.; Kraatz, G.; Lhotta, K.; Mann, JFE; Mueller, Gerhard A. ; Neyer, U.; Riegel, W.; Riegler, P.; Schwenger, V.; von Eckardstein, Arnold
- Abstract
- Cell culture studies and investigations in mice that overexpress either human or mouse apolipoprotein A-I-V (apoA-IV) revealed anti-atherogenic properties of apoA-IV. An association between low apoA-IV concentrations and coronary artery disease in humans was demonstrated; therefore, apoA-IV may also play an antiatherogenic role in humans. Because apoA-IV is markedly elevated in dialysis patients, patients with the earliest and modest stages of renal impairment were studied to assess the association of apoA-IV with GFR and atherosclerotic complications. GFR was measured by the use of iohexol in 227 non-nephrotic patients with different degrees of renal impairment. ApoA-IV increased significantly with decreasing GFR and was already elevated in earliest stages of renal disease (GFR > 90 ml/mn per 1.73 m(2)). Multiple linear regression analysis identified renal function parameters (GFR, creatinine, and urea) as the most important determinants of apoA-IV levels in serum of these patients. Twenty-six patients had already experienced 36 atherosclerotic events. Logistic regression analysis identified three variables associated with atherosclerotic complications: age, apoA-IV, and gender. Each 1 mg/dl increase of apoA-IV decreased the odds ratio for an atherosclerotic complication by 8% (P = 0.011). The data clearly show that the anti-atherogenic apoA-IV starts to increase during the earliest phases of renal insufficiency, which makes apoA-IV an early marker of renal impairment.
- Issue Date
- 2002
- Status
- published
- Publisher
- Amer Soc Nephrology
- Journal
- Journal of the American Society of Nephrology
- ISSN
- 1046-6673